Please use a PC Browser to access Register-Tadawul
Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment
Regeneron Pharmaceuticals, Inc. -0.74%
Regeneron Pharmaceuticals, Inc. REGN | 741.29 | -0.74% |
Under the terms of the agreement, Mammoth will receive $100 million inclusive of $95 million in equity investment at signing, and an upfront payment, and is eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, and royalty rates ranging from single digits to mid-teens on future net sales of all collaboration products.


